For thousands of people living with treatment resistant schizophrenia, clozapine remains the most effective medication available, yet the drug’s lifesaving potential has long been overshadowed by a demanding routine of weekly blood tests that many patients find burdensome. A major new study from Hong Kong suggests that this monitoring schedule could be safely relaxed much sooner than current guidelines recommend, offering hope for a less intrusive treatment path.

Clozapine is widely regarded as the gold standard for patients who have not responded to other antipsychotics. Its use, however, carries a small risk of neutropenia, a drop in white blood cells that can leave patients vulnerable to infection. To catch this early, doctors typically require weekly blood tests for at least the first six months of treatment, with some health systems continuing this practice indefinitely.

Researchers at the University of Hong Kong analysed two decades of health records covering more than 43,000 patients with schizophrenia, including nearly 4,900 people who started clozapine and over 38,000 who took other second generation antipsychotics. The study, published in The British Journal of Psychiatry, followed patients for a median of almost nine years, making it one of the longest and largest comparisons of its kind.

The findings showed that clozapine users did face a higher risk of both minor and serious neutropenia, but almost entirely within the first eighteen weeks of starting treatment. After this initial period, the risk dropped sharply and, by around two years, was statistically similar to that seen in patients taking other antipsychotics. Using statistical modelling, the team identified clear turning points in risk at roughly twenty six to twenty nine weeks, again at around one year, and once more between eighteen months and two and a half years.

Notably, the increased risk of serious neutropenia was not significant in patients under forty five, suggesting that age may play an important role in how the body responds to the drug. Men showed a temporary rise in minor neutropenia risk between one and two years of treatment, a pattern the researchers said warrants further investigation.

Deaths linked to neutropenia were rare and did not differ meaningfully between the two groups, reinforcing the view that clozapine’s blood related risks are manageable when properly monitored. The authors argue their results support recent moves in Europe and the United States to ease monitoring requirements, recommending weekly testing for 18 weeks followed by monthly checks until the two year mark, after which surveillance could be folded into routine annual health reviews.

For patients and clinicians alike, the implications are significant. Reducing the burden of frequent blood draws could remove a major barrier to starting clozapine, a drug known to reduce hospital admissions and lower mortality, potentially widening access to this vital treatment for people with the most difficult to treat forms of schizophrenia.